The mutation rate of NOTCH1 gene in subgroup B (23%) is higher than that in other groups, which may be the reason why HNSCC patients in subgroup B have worse OS than those in subgroup C. It also means that some HNSCC patients may benefit from anti-NOTCH1 therapy. The gene discussed is NOTCH1; the disease is head and neck squamous cell carcinoma.